Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 5 , Pages 429-438 , September 2010

Evaluation and Pharmacologic Management of the HIV-Infected Patient With Dyslipidemia

References 

  1. Aberg J, Zackin R, Brobst S, Evans S, Alston B, Henry WK, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trial Group Study 5087. AIDS Research and Human Retroviruses. 2005;21:757–767
  2. Anastos K, Lu D, Shi Q, Tien P, Kaplan R, Hessol N, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. Journal of Acquired Immune Deficiency Syndromes. 2007;45:34–42doi:10.1097/QAI.0b013e318042d5fe
  3. Aslangul, E., Assoumou, K., Bittar, R., Valatin, M., Klamykova, O., Peytavin, M., … Costagliola, D. (2007, October). A prospective, randomized open label trial comparing the efficacy and safety of rosuvastatin versus pravastatin in HIV-infected subjects receiving ritonavir boosted PI with lipid abnormalities. Poster session presented at the 11th European AIDS Conference, Madrid, Spain.
  4. Badaro R, DeJesus E, Lazzarin A, Jemsek J, Clotet B, Rightmire A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424–045. Antiviral Therapy. 2003;8(Suppl. 1):
  5. Baker J, Henry W, Neaton J. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: Shifting paradigms. Current Opinion in HIV & AIDS. 2009;4:176–182
  6. Bedimo, R., Westfall, A., Drechsler, H., & Tebas, P. (2009, July). Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the ART era (Abstract MOAB202). Poster session presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009), Cape Town, South Africa.
  7. Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R, Klinker H, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir. Infection. 2004;32:229–233
  8. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson A, Lambert P, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. Journal of the American Medical Association. 2008;300:51–59
  9. Burger D, Stroes E, Reiss P. Drug interactions between statins and antiretroviral agents. Current Opinion in HIV and AIDS. 2008;3:247–251
  10. Centers for Disease Control and Prevention. (2006). Table 6. Number of new AIDS diagnoses in adolescents and adults, by age at AIDS diagnosis and race/ethnicity—United States, 2000. Retrieved from http://www.cdc.gov/hiv/topics/over50/resources/factsheets/over50.htm
  11. Cutrell, A., Hernandez, J., Yeo, J., Brothers, C., Burkle, W., & Spreen, W. (2008, August). Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials. Poster session presented at the XVII International AIDS Conference, Mexico City, Mexico.
  12. DeJesus, E., Walmsley, S., Cohen, C., Cooper, D., Hirschel, B., Goodrich, J., … Mayer, H. (2008, February). Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naïve HIV-infected patients. Poster session presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  13. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave J, et al. Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy. AIDS. 2001;15:329–334
  14. De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: A randomized prospective study. Journal of Acquired Immune Deficiency Syndrome. 2007;44:278–285
  15. Dubé M, Stein J, Aberg J, Fichtenbaum C, Gerber J, Tashima K, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Disease. 2003;37:613–627
  16. El-Sadr W, Mullin C, Carr A, Gilbert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naïve cohort. HIV Medicine. 2005;6:114–121
  17. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917–925
  18. Fischl M, Collier A, Mukherjee A, Feinberg J, Demeter L, Tebas P, et al. Randomized open-label trial of two simplified, class sparing regimens following first suppressive three or four-drug regimen. AIDS. 2007;21:325–333
  19. Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine. 2007;356:1723–1735
  20. Garcia-Benayas T, Blanco F, Alcolea A, De la Cruz J, Gonzalez-Lahoz J, Soriano V. Benefits in the lipid profile after substitution of abacavir for stavudine: A 48 week prospective study. AIDS Research and Human Retroviruses. 2004;20:1289–1292
  21. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine. 2005;352:48–62
  22. Haubrich, R., Riddler, S., DiRienzo, G., Komarrow, L., Powderly, W., Mellors, J., … Klingman, K. (2007, February). Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Poster session presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
  23. Klein, D., Hurley, L., Quesenberry, C., & Sidney, S. (2006, February). Hospitalizations for CHD and MI among Northern California HIV+ and HIV- men: Additional follow-up and changes in practice and Framingham risk scores. Poster session presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
  24. Krentz H, Kliewer G, Gill M. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984-2003. HIV Medicine. 2005;6:99
  25. Law M, Friis-Moller N, El-Sadr W, Weber R, Reiss P, Arminio A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D: A:D study. HIV Medicine. 2006;7:218–230
  26. Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. The Lancet. 2007;370:29–38doi: 10.1016/S0140-6736(07)61047-2
  27. Markowitz M, Nguyen B, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: Results of a 48-week controlled study. Journal of Acquired Immune Deficiency Syndrome. 2007;46:125–133
  28. Martinez E, Conget I, Lozana L, Casamitjana R, Gatell J. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810
  29. Martinez E, Leyes P, Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Current Opinion in HIV and AIDS. 2008;3:240–246
  30. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor associated hypertriglyceridemia. AIDS. 2002;16:2195–2200
  31. Moyle G, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard B. Dietary advice with or without pravastatin for the management of hypercholesterolemia-associated with protease inhibitor therapy. AIDS. 2001;15:1503–1508
  32. National Heart Lung Blood Institute. (2004). 10-year CVD risk calculator. Retrieved from http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof
  33. National Heart Lung Blood Institute. (2005). High blood cholesterol: What you need to know. Retrieved from http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm
  34. Neuman T. HIV and Cardiac Diseases. In:  Hoffman C,  Rockstroh J,  Kamps B editor. HIV medicine 2007. Paris, France: Flying Publisher; 2007;p. 617–626
  35. Sabin C, Worm S, Weber R, Reiss P, El Sadr W, Dabis S, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A:D study. Lancet. 2008;371:1417–1426
  36. Sackoff J, Hanna D, Pfeiffer M, Torian L. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Annals of Internal Medicine. 2006;145:397–406
  37. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clinical Infectious Disease. 2003;37:292–298
  38. Tebas P, Zhang J, Yarasheski K, Evans S, Fischl M, Shevitz A, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS Clinical Trials Group 5125s). Journal of Acquired Immune Deficiency Syndrome. 2007;45:193–200
  39. The SMART/INSIGHT & the D: A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24
  40. U.S. Department of Health and Human Services. (2004). Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III final report). Retrieved from http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm
  41. U.S. Department of Health and Human Services. Panel on antiretroviral guidelines for adult and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008;Retrieved from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
  42. van der Valk, M., Friis-Moller, N., Sabin, C., Dabis, F., D'Arminio Monforte, A., Weber, R., & Katlama, C. (2006, November). Effect of interventions to improve dyslipidemia. Poster presented at the 8th International Congress on Drug Therapy in HIV infection, Glasgow, UK.
  43. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Medicine. 2004;1:e19
  44. Wohl, D., Hsue, P., Richard, S., Schnell, A., Napravnik, S., Simpson, R., & Hsue, P. (2007, February). Ezetimibe's effects on the LDL-cholesterol levels of HIV-infected patients receiving ART. Poster presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
  45. Wood R, Arasteh K, Stellbrink H, Teofilo E, Raffi F, Pollard R, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type-1-Infected patients. Antimicrobial Agents and Chemotherapy. 2004;48:116–123

PII: S1055-3290(09)00234-9

doi: 10.1016/j.jana.2009.12.006

Journal of the Association of Nurses in AIDS Care
Volume 21, Issue 5 , Pages 429-438 , September 2010

Article Tools